Skip to main content

ADHD Awareness Month – Message from Purdue Pharma (Canada)

Published on - October 4, 2019

October is ADHD Awareness Month. According to the Centre for ADHD Awareness, Canada, more than…

Read More >

AKYNZEO ® Oral now covered by the Ontario, Quebec and Non-Insured Health Benefits

Published on - July 10, 2019

Pickering, Ontario (July 10, 2019) – Purdue Pharma (Canada) is pleased to announce that AKYNZEO®…

Read More >

Message from Purdue Pharma (Canada)

Published on - April 9, 2019

The Canadian Cancer Society has designated April Cancer Awareness Month.  According to the Society, cancer…

Read More >

FOQUEST® RECEIVES APPROVAL FOR EXPANDED INDICATION FOR CHILDREN AND ADOLESCENTS WITH ADHD

Published on - March 12, 2019

First and only methylphenidate product approved in Canada that provides control of ADHD symptoms throughout…

Read More >

PURDUE PHARMA (CANADA) RESPONSE TO FEDERAL MINISTER OF HEALTH

Published on - June 29, 2018

In response to a request from the Federal Minister of Health, in a letter dated…

Read More >

Purdue Pharma (Canada) appoints Dr. Tom Koutsavlis as new Vice President, Research and Development

Published on - July 5, 2017

PICKERING, ON, July 5, 2017 /CNW/ – Dr. Tom Koutsavlis, MD, MSc, FRCPC, MBA, has…

Read More >

Dr. Craig Landau Appointed President and CEO Purdue Pharma L.P.

Published on - June 22, 2017

Dr. Craig Landau Appointed President and CEO Purdue Pharma LP. Read the Press Release issued…

Read More >

Voluntary Payments Disclosure

Published on - June 20, 2017

Today, (June 20, 2017) Purdue Pharma (Canada) voluntarily published aggregated sums of payments made to…

Read More >

Helsinn Group signs Exclusive Agreement with Purdue Pharma (Canada) for the Distribution and Licensing Rights of Aloxi® (palonosetron hydrochloride) in Canada

Published on - June 6, 2017

Lugano, Switzerland and Pickering, Canada, June 6, 2017 – Helsinn Group and Purdue Pharma (Canada)…

Read More >
↓